These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11384568)

  • 1. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma.
    Konstas AG; Stewart WC; Topouzis F; Tersis I; Holmes KT; Stangos NT
    Am J Ophthalmol; 2001 Jun; 131(6):729-33. PubMed ID: 11384568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
    Katz LJ
    Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
    Schuman JS
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
    Sharpe ED; Henry CJ; Mundorf TK; Day DG; Stewart JA; Jenkins JN; Stewart WC
    Eye (Lond); 2005 Jan; 19(1):35-40. PubMed ID: 15094733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
    Javitt JC; Schiffman RM
    J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
    Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
    Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily.
    Stewart WC; Stewart JA; Day D; Sharpe ED
    Acta Ophthalmol Scand; 2003 Jun; 81(3):242-6. PubMed ID: 12780402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
    Yüksel N; Altintaş O; Karabaş L; Alp B; Cağlar Y
    Ophthalmologica; 1999; 213(4):228-33. PubMed ID: 10420106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
    Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A
    Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma.
    Konstas AG; Maltezos AC; Gandi S; Hudgins AC; Stewart WC
    Am J Ophthalmol; 1999 Jul; 128(1):15-20. PubMed ID: 10482089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
    Konstas AG; Maltezos A; Mantziris DA; Sine CS; Stewart WC
    Eye (Lond); 1999 Jun; 13 ( Pt 3a)():314-8. PubMed ID: 10624424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
    Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
    Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol.
    Konstas AG; Nakos E; Tersis I; Lallos NA; Leech JN; Stewart WC
    Am J Ophthalmol; 2002 Jun; 133(6):753-7. PubMed ID: 12036665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.